ReviewDrug design, development and therapy2026
The Role and Mechanism of SGLT2 Inhibitors in Chronic Kidney Disease.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) refers to structural or functional abnormalities of the kidneys caused by various factors lasting ≥3 months, or a decline in glomerular filtration rate (GFR) of <60 mL/min of unknown cause lasting ≥3 months. Its primary causes include diabetic kidney disease, hypertensive nephropathy, IgA nephropathy, membranous nephropathy, and lupus nephritis, among others. As a new class of antidiabetic drugs, sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown in numerous clinical studies and animal experiments to be effective in treating CKD of various etiologies. The renoprotective effects of SGLT2 inhibitors are independent of their glucose-lowering effects. Through mechanisms such as hemodynamics, oxidative stress, and anti-fibrosis, they reduce serum creatinine and urinary protein levels, thereby slowing the progression of CKD. This review primarily summarizes clinical and basic research on SGLT2i in the treatment of CKD and analyzes the signaling pathways through which SGLT2i exerts its effects on CKD. This demonstrates that SGLT2 inhibitors can delay the progression of kidney function decline and improve outcomes in patients across various subtypes through multiple mechanisms. They are suitable for patients with CKD of different etiologies and across different estimated glomerular filtration rate (eGFR) categories, indicating the significant potential and promising prospects for the widespread use of SGLT2 inhibitors in patients with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.